An adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of associated clinical manifestations, such as cachexia and the correction of adverse effects of drugs and treatments, such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier and compounds with antineoplastic action and/or other treatments characterized as an association or combination of substances for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, including a biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) as a fixed component for prior, concomitant or subsequent use, or in drug formulations with at least one other pharmacologically active compound or substance and/or non-drug treatments. The referred pharmacologically active substances or compounds can be selected among the main classes or categories, cited here for illustrative purposes only and by no means constituting an exhaustive list:
- Alkylating agents, such as nitrogen mustards (mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil), ethyleneimines and methylmelamines (thiotepa and hexamethylmelamine), alkyl sulphonates (busulfan), nitrosureas (carmustine and streptozocin), triazenes (dacarbazine and temozolimide), platinum complexes (cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, satraplatin), antimetabolites such as folic acid antagonists (methotrexate, trimethoprim, pyrimethamine), purine analogues (azathioprine, mercaptopurine, thioguanine, fludarabine, pentostatin, cladribine), pyrimidine analogues (5-fluorouracil (5-FU), gemcitabine, floxuridin, cytarabine), mitotic inhibitors such as vinca alkaloids (vinblastine, vincristine, vindesine, vinorelbine), terpenoids (taxane, paclitaxel, docetaxel, larotaxel), antitumor antibiotics (daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, hydroxyurea), topoisomerase inhibitors (irinotecam, topotecan, amsacrine, etoposide, etoposide phosphate, teniposide), tyrosine kinase blockers (erlotinib, gefitinib, imatinib, sunitinib, sorafenib), hormones (dexamethasone, finasteride, tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, megestrol, goserelin, leuprolide, diethylstilbestrol), monoclonal antibodies (alemtuzumab, bevacizumab, cetuximab, ocrelizumab, ofatumumab, panitumumab, rituximab, trastuzumab) monoclonal antibodies conjugated with radioactive particles (ibritumomab tiuxetan, tositumomab), angiogenesis inhibitors (bevacizumab), stimulation factors of the myeloid lineage (filgrastim, pegfilgrastim, lenograstim, molgramostim, sargramostim) cytokines (interleukin-2 (IL-2), interleukin 12 (IL-12), interferon alpha, interferon alpha-2a, peginterferon alpha-2a, interferon alpha-2b, peginterferon alpha-2b, interferon alpha-n1, interferon alphacon-1, interferon beta, interferon beta-1a, interferon beta-1b, tumor necrosis factor (TNF), immunotherapeutic drugs (BCG vaccine and derivatives, levamisole, isoprinosine), biological response modifiers (imiquimod and resiquimod), therapeutic vaccines for cancer (autoimmune vaccines, dendritic cell vaccines), enzymes (L-asparaginase) polyunsaturated fatty acids or Pufas (eicosaminopentoic acid—EPA, linoleic acid docosahexanenoic acid—DHA), aminoacids (arginine, glutamine), steroids (megestrol acetate), steroidal anti-inflammatory drugs (hydrocortisone, cortisone, corticosterone, dexamethasone, betamethasone, prednisolone, prednisone, methylprednisolone, budesonide, beclomethasone), derivatives of tetrahydrocannabinol (dronabinol), non-steroidal anti-inflammatory drugs (ibuprofen), enzyme inhibitors (eicosapentaenoic acid, hydrazine sulfate), hormones (melatonin, somatropin) and others, and non-drug treatments can be selected among the following classes or categories, cited as exemplification and by no means constituting an exhaustive list:
- surgical procedures (surgery, cryosurgery, electrocauterization, surgery associated to polarized light or laser with the use of photosensitizing substances, endoscopic radiofrequency ablation with the use of balloon catheter, removal of lesions by chemical abrasion, transplantation of bone marrow cells and stem cells, systemic and localized radiotherapy) and other compounds or substances not specified. All the classes or categories of pharmacologically active substances and/or classes or categories of non-drug treatments can be selected for use in the present invention, alone or in combination or association with each other.